Search research articles
Contact Us
Filters
Showing results (301-310 of 453) with videos related to
Page
of 46
Sort By:
Journal of Neuro-Oncology
|
April 11, 2015
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)
Mariko DeWire, Maryam Fouladi, David C Turner, et al.
Neuro-Oncology
|
December 6, 2013
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection
Jason Beiko, Dima Suki, Kenneth R Hess, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 6, 2017
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525
Wenyin Shi, Molly Scannell Bryan, Mark R Gilbert, et al.
Neuro-Oncology
|
January 3, 2018
Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma
Shuyu Hao, Hua Song, Wei Zhang, et al.
Neuro-Oncology
|
June 13, 2017
MerTK as a therapeutic target in glioblastoma
Jing Wu, Lauren N Frady, Ryan E Bash, et al.
Acta Neuropathologica
|
February 22, 2015
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas
Adriana Olar, Khalida M Wani, Kristin D Alfaro-Munoz, et al.
The Lancet. Oncology
|
February 3, 2020
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report
Terri S Armstrong, Linda Dirven, David Arons, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
April 7, 2022
Targeting selenoprotein H in the nucleolus suppresses tumors and metastases by Isovalerylspiramycin I
Jing Cui, Jingcheng Zhou, Weiqing He, et al.
Neuro-Oncology
|
January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival
Benjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.
JNCI Cancer Spectrum
|
March 28, 2025
Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review
Amanda L King, Tamara Vasilj, Diane Cooper, et al.
Page
of 46
Search research articles
Search
Showing results (301-310 of 453) with videos related to
Sort By:
Page
of 46
Journal of Neuro-Oncology
|
April 11, 2015
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)
Mariko DeWire, Maryam Fouladi, David C Turner, et al.
Neuro-Oncology
|
December 6, 2013
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection
Jason Beiko, Dima Suki, Kenneth R Hess, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 6, 2017
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525
Wenyin Shi, Molly Scannell Bryan, Mark R Gilbert, et al.
Neuro-Oncology
|
January 3, 2018
Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma
Shuyu Hao, Hua Song, Wei Zhang, et al.
Neuro-Oncology
|
June 13, 2017
MerTK as a therapeutic target in glioblastoma
Jing Wu, Lauren N Frady, Ryan E Bash, et al.
Acta Neuropathologica
|
February 22, 2015
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas
Adriana Olar, Khalida M Wani, Kristin D Alfaro-Munoz, et al.
The Lancet. Oncology
|
February 3, 2020
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report
Terri S Armstrong, Linda Dirven, David Arons, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
April 7, 2022
Targeting selenoprotein H in the nucleolus suppresses tumors and metastases by Isovalerylspiramycin I
Jing Cui, Jingcheng Zhou, Weiqing He, et al.
Neuro-Oncology
|
January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival
Benjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.
JNCI Cancer Spectrum
|
March 28, 2025
Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review
Amanda L King, Tamara Vasilj, Diane Cooper, et al.
Page
of 46